A common variant near TGFBR3 is associated with primary open angle glaucoma

Grants

Funding Acknowledgements

We thank all the study participants, the staff from all involved studies and sites who contributed to this study. The authors J.E.C., K.P.B., D.A.M., and others acknowledge the support of Ms Bronwyn Usher-Ridge in patient recruitment and data collection, and Dr Patrick Danoy and Dr Johanna Hadler for genotyping of the ANZRAG cohort. They also acknowledge David C. Whiteman and Graham Radford-Smith for providing access to the control samples used with the ANZRAG glaucoma cases. The authors D.M. thank Dr Philippe Gohier and Dr Ghislaine Jallet for patient recruitment and data collection and acknowledge the technical assistance provided by the Centre de Recherche Biologique (Dr Odile Blanchet) and Centre de Recherche Clinique (Pr Marc-Antoine Custeau), University Hospital, Angers, France. The Singapore study of E.N.V., T.A. and C.C.K was supported by a Biomedical Research Council (BMRC) grant in Singapore, Ref: BMRC 10/1/35/19/675. This research was also partly supported by a grant (NMRC/TCR/008-SERI/2013) from the Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council. We also acknowledge the following source of funding support for recruitment and genotyping of population-based cohorts SIMES and SCES: National Medical Research Council, Singapore (NMRC/TCR/002-SERI/2008, (R626/47/2008TCR), CSA R613/34/2008, NMRC 0796/2003, STaR/0003/2008), the National Research Foundation of Singapore, the Biomedical Research Council, Singapore (BMRC 09/1/35/19/616 and 08/1/35/19/550) and Genome Institute of Singapore (GIS/12-AR2105). The Singapore Tissue Network and the Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore provided services. The research of M.A.H. was supported by NIH R01 EY023646, EY13315 (MAH) and by P30-EY005722. The Japanese sample collection from Kyoto was supported by the grants from the Collaborative Development of Innovative Seeds of Japan Science and Technology Agency (JST) to M.K. and K.T., from the Ministry of Health, Labor and Welfare of Japan to M.N., K.M., K.T. and S.K., and from Santen Pharmaceutical Co. Ltd. to S.K. and K.T. The collection of Japanese POAG cases by N.F. was supported by a grant provided by the Ministry of Health, Labor and Welfare of Japan. The glaucoma research of WNL is supported by National Natural Science Foundation of China project (81030016). The research of Y. Chen was supported by National Natural Science Foundation of China (81200723) and glaucoma research of Xinghuai Sun was supported by Special Scientific Research Project of Health Professions (201302015). This research project was supported by the National Natural Science Foundation of China (81170883 (Z. Y.) and 81430008 (Z. Y.)). The glaucoma research of C.P.P. is supported by the Health and Medical Research Fund (HMRF, Ref: 01122236 and 11120801), Hong Kong and the General Research Fund from the Research Grants Council (grant number 468810), Hong Kong. Support for recruitment of Australian & New Zealand Registry of Advanced Glaucoma (ANZRAG) was provided by the Royal Australian and New Zealand College of Ophthalmology (RANZCO) Eye Foundation. Genotyping was funded by the National Health and Medical Research Council of Australia (#535074 and #1023911). This workwas also supported by funding from NHMRC #1031362 awarded to Jamie E. Craig, NHMRC #1037838 awarded to Alex W. Hewitt, NHMRC # 1048037 awarded to Stuart L. Graham, NHMRC # 1009844 awarded to Robert J.Casson and Ivan Goldberg, NHMRC # 1031920 and an Alcon Research Institute grant awarded to David A. Mackey, an Allergan Unrestricted grant awarded to Andrew J. White, the BrightFocus Foundation and a Ramaciotti Establishment Grant. S.M. is supported by Australian Research Council (ARC) and Australian National Health & Medical Research Council (NHMRC) Fellowships. Controls for the ANZRAG discovery cohort were drawn from the Australian Cancer Study, the Study of Digestive Health, and from a study of inflammatory bowel diseases. The Australian Cancer Study was supported by the Queensland Cancer Fund and the National Health and Medical Research Council (NHMRC) of Australia (Program no. 199600, awarded to David C. Whiteman, Adele C. Green, Nicholas K. Hayward, Peter G. Parsons, David M. Purdie and Penelope M. Webb, and program number 552429, awarded to David C. Whiteman). The Study of Digestive Health was supported by grant number 5 RO1 CA 001833 from the National Cancer Institute (awarded to David C. Whiteman). The Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS) sponsored the genotyping of oesophageal cancer and Barrett's oesophagus cases, which were used as unscreened controls in the ANZRAG discovery cohort. BEAGESS was funded by grant R01 CA136725 from the National Cancer Institute Collection of Saudi POAG cases and controls was supported by the Glaucoma Research Chair at College of Medicine, King Saud University, Riyadh, Saudi Arabia. NEI Glaucoma Human Genetics Collaboration (NEIGHBOR): genotyping services for the NEIGHBOR study were provided by the CIDR and were supported by the NEI through grant HG005259-01 (J.L.W.). Additionally, CIDR is funded through a federal contract from the NIH to The Johns Hopkins University, contract number HHSN268200782096C. Collecting and processing samples for the NEIGHBOR data set was supported by the NEI through American Recovery and Reinvestment Act (ARRA) grants 3R01EY015872-05S1 (J.L.W.) and 3R01EY019126-02S1 (M.A.H.). Genotype imputation and meta-analysis were supported by EY022305 (J.L.W.). Funding for the collection of cases and controls was provided by the following NIH grants: EY015543 (R.R. Allingham); EY006827 (D. Gaasterland); HL73042, HL073389, EY13315, EY023646 (M. A. H.); CA87969, CA49449, UM1 CA167552 (J.H. Kang); EY009149 (P.R. Lichter); HG004608 (C. McCarty); EY008208 (F.A. Medeiros); EY015473 (L.R.P.); EY012118 (M. Pericak-Vance); EY015682 (A. Realini); EY011671, EY09580 (J.E. Richards); EY013178 (J. S. Schuman); RR015574, EY015872, EY010886, EY009847, EY014104 (J.L.W.); EY011008, EY144428, EY144448 and EY18660 (K. Zhang). J.L.W. and L.R.P. are also supported by the Harvard Glaucoma Center for Excellence and Research to Prevent Blindness. J.N.C.B. is supported by NIH T32 EY007157 (CWRU) and T32 EY21453-2 (VUMC). MEEI case-control sample: genotyping for the Massachusetts Eye and Ear Infirmary (MEEI) case-control sample was performed at the Broad Institute of MIT and Harvard with funding support fromthe NIH GEI (Gene Environment Initiative) (U01HG04424 and U01HG004728). The GENEVA Coordinating Center (U01HG004446) assisted with genotype cleaning. Imputation was supported by NIH EY022305 (JLW). Collection of cases and controls was supported by NIH EY015872 (JLW) and NIH P30 014104 (JLW). Funding to pay the Open Access publication charges for this article was provided by Singapore Eye Research Institute.